12 May 2015 16:26
SKYEPHARMA PLC - RESULT OF AGM
LONDON, UK, 12 May 2015 - Skyepharma PLC (LSE: SKP) announces the results of the voting by shareholders at the Annual General Meeting held earlier today. All resolutions were passed with the requisite majorities on a show of hands.
In accordance with Listing Rule 9.6.2, a copy of the resolutions passed, other than resolutions concerning ordinary business, will shortly be submitted to the National Storage Mechanism, and will be available for inspection at www.morningstar.co.uk/uk/NSM
The full text of all the resolutions passed at the meeting can be found in the Notice of Annual General Meeting, which is available for inspection at www.morningstar.co.uk/uk/NSM and on the Company's website at www.skyepharma.com.
Full details of the proxy voting will be available on our website (www.skyepharma.com) later today.
For further information please contact:
Skyepharma PLC | Peter Grant, Chief Executive Officer | +44 20 7881 0524 |
John Murphy, Group Counsel and Company Secretary | ||
Jonathan Birt, Investor and Media Relations | +44 (0)7860 361746 | |
Financial Dynamics | Julia Phillips | +44 (0)20 3727 1000 |
Natalie Garland-Collins | ||
About Skyepharma
Skyepharma combines proven scientific expertise with validated proprietary technologies to develop innovative oral and inhalation pharmaceutical products. The Group's licenses cover 16 approved inhalation, oral, topical and injectable products, which generate milestones, recurring royalties, and in some cases, product supply revenues. The Group also earns milestones and contract development revenues from new product developments. Products developed by Skyepharma are marketed by some of the world's most respected pharmaceutical companies. For more information, visit www.skyepharma.com